The two main types of cannabinoid receptors are CB1 and CB2. CB1 receptors sit on nerve cells in the brain and central nervous system, while CB2 receptors sit on immune cells and tissue such as the spleen. A few other proteins, including GPR55, TRPV1, and PPARs, also react to cannabinoids, but they are not part of the classic cannabinoid receptor family.
CB1 receptors: the brain and central nervous system
CB1 is one of the most common G protein-coupled receptors in the brain. It shows up in the cerebral cortex, hippocampus, cerebellum, basal ganglia, and spinal cord, which lines up with its role in memory, movement, mood, and pain processing.
One place CB1 stays scarce is the brainstem, the region that controls breathing. That low density is part of why cannabinoids do not shut down respiration the way opioids can.
- Memory and learning
- Motor control
- Appetite and food intake
- Pain perception
- Mood and stress response
- Body temperature and sleep
CB2 receptors: the immune side of the system
CB2 appears on macrophages, B cells, T cells, and microglia, the immune cells of the brain. The receptor also sits in the spleen, tonsils, and thymus.
CB2 activation tends to calm immune activity. Research links CB2 signaling to lower release of inflammatory cytokines and to changes in how pain signals travel. Cancer studies target CB2 because some tumors of the immune system carry the receptor in high numbers.
How do cannabinoid receptors send signals?
Both CB1 and CB2 are G protein-coupled receptors. When a cannabinoid locks onto one, the receptor changes shape and triggers G proteins inside the cell. Those G proteins then lower cyclic AMP and shift ion channels, which changes how excitable the cell becomes.
The body's own cannabinoids, anandamide and 2-AG, are made on demand and released from the postsynaptic neuron. They travel backward across the synapse and bind CB1 on the neuron that just fired, turning down the release of other neurotransmitters. This backward (retrograde) signaling is why endocannabinoids work as a brake instead of a gas pedal.
Which other receptors respond to cannabinoids?
Several receptors interact with THC, CBD, and endocannabinoids even though they carry other names. The list keeps growing as research moves forward, and a few targets remain under debate.
- GPR55: some older papers called it CB3, though most reviewers reject that label. It responds to certain cannabinoids and plays a role in bone and blood vessel function.
- TRPV1: the capsaicin receptor, tied to heat and pain sensing. CBD and anandamide both act here.
- PPAR-alpha and PPAR-gamma: nuclear receptors linked to metabolism and inflammation. CBD and THC can activate them.
- 5-HT1A: a serotonin receptor that CBD binds. This target may explain some of the reported effects of CBD on anxiety and mood.
- GPR18 and GPR119: two orphan receptors found in immune and metabolic tissue that respond to endocannabinoid-like molecules.
- Adenosine A2A and glycine receptors: extra targets that cannabinoids can touch at higher concentrations.
CB1 vs CB2: how the two receptor types differ
- Location: CB1 works in the brain and nerves; CB2 works in immune tissue.
- Abundance: CB1 is one of the most common receptors in the brain; CB2 levels rise when the immune system is active.
- Psychoactivity: CB1 activation produces the THC high; CB2 activation does not.
- Signaling: both couple to Gi/o proteins, but they trigger different downstream paths in different tissues.
- Drug interest: CB1 blockers were tested for obesity, while CB2 agonists are studied for pain and inflammation.
Do THC and CBD bind to the same receptors?
THC binds CB1 and CB2 as a partial agonist, meaning it switches the receptors on but not at full power. That CB1 activity drives the high, along with effects on appetite, memory, and pain.
CBD has low affinity for both CB1 and CB2, so it does not switch them on in the same way. CBD works as a negative allosteric modulator at CB1, which changes the shape of the receptor and can blunt some THC effects. CBD also blocks the enzyme FAAH, which breaks down anandamide, so more of the body's own cannabinoid stays in circulation.
Much of CBD's best-documented receptor activity happens outside the CB1 and CB2 pair, at TRPV1, 5-HT1A, and PPAR-gamma.
Why receptor types matter when you buy CBD
Receptor science explains why a product label says more than the CBD number. THC binds CB1 and CBD does not, so a full-spectrum oil with THC will feel different from a CBD isolate at the same CBD dose.
- Full-spectrum: contains THC (up to 0.3% in the US), so CB1 activity is possible. Pick this if you want the whole plant profile.
- Broad-spectrum: THC removed, other cannabinoids kept. No CB1-driven high.
- Isolate: pure CBD, described as THC-free. A fit for people who need to pass a drug test or who want to avoid THC.
- Lab reports: a certificate of analysis shows the cannabinoid profile and confirms THC content, heavy metals, and pesticides.
Whatever you choose, check the batch COA. Third-party testing is the practical way to know what your receptors are getting.
Frequently asked questions about cannabinoid receptors
How many types of cannabinoid receptors are there?
Two receptors, CB1 and CB2, are accepted as cannabinoid receptors. A handful of related targets (GPR55, TRPV1, PPARs, 5-HT1A) respond to cannabinoids but are grouped under other receptor families.
Where are CB1 receptors found?
CB1 sits on neurons in the cerebral cortex, hippocampus, cerebellum, basal ganglia, and spinal cord. It also appears in peripheral tissue such as the liver, fat, and gut, though at lower density than in the brain.
Does CBD activate CB2 receptors?
CBD binds CB2 with low affinity, so direct activation is weak. Most of the immune-related activity tied to CBD traces to other targets and to its ability to raise endocannabinoid levels.
Do all cannabinoids bind the same receptors?
No. THC binds CB1 and CB2 with moderate affinity, CBD does not, and compounds such as CBG and CBN show weak activity at both receptors while acting on other targets.
Is there a CB3 receptor?
No receptor holds that name in current pharmacology. Some early papers used CB3 for GPR55, but the label did not stick because GPR55 differs from CB1 and CB2 in structure and signaling.